Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 484

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Open access
Domchek, Susan M, Postel-Vinay, Sophie, Im, Seock-Ah, Park, Yeon Hee, Delord, Jean-Pierre, Italiano, Antoine, Alexandre, Jerome, You, Benoit, Bastian, Sara, Krebs, Matthew G, Wang, Ding, Waqar, Saiama N, Lanasa, Mark, Rhee, Joon, Gao, Haiyan, Rocher-Ros, Vidalba, Jones, Emma V, Gulati, Sakshi, Coenen-Stass, Anna, Kozarewa, Iwanka, Lai, Zhongwu, Angell, Helen K, Opincar, Laura, Herbolsheimer, Pia, Kaufman, Bella·2020·The Lancet Oncology

Abstract

BACKGROUND Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer. METHODS The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in solid tumours. Patients were enrolled into four initial cohorts: germline BRCA-mutated, metastatic breast cancer; germline BRCA-mutated, metastatic ovarian cancer; metastatic gastric cancer; and relapsed small-cell lung cancer. Here, we report on the cohort of patients with breast cancer. Patients who were aged 18 years or older (or aged 19 years or older in South Korea) with germline BRCA1-mutated or BRCA2-mutated or both and histologically confirmed, progressive, HER2-negative, metastatic breast cancer were enrolled from 14 health centres in the UK, the USA, Israel, France, Switzerland, and South Korea. Patients should not have received more than two previous lines of chemotherapy for metastatic breast cancer. Patients received 300 mg olaparib in tablet form orally twice daily for 4 weeks and thereafter a combination of olaparib 300 mg twice daily and durvalumab 1·5 g via intravenous infusion every 4 weeks until disease progression. Primary endpoints were safety and tolerability, and 12-week disease control rate. Safety was analysed in patients who received at least one dose of study treatment, and activity analyses were done in the full-analysis set (patients who received at least one dose of study treatment and were not excluded from the study). Recruitment has completed and the study is ongoing. This trial is registered with ClinicalTrials.gov, NCT02734004. FINDINGS Between June 14, 2016, and May 2, 2017, 34 patients were enrolled and received both study drugs and were included in the safety analysis. 11 (32%) patients experienced grade 3 or worse adverse events, of which the most common were anaemia (four [12%]), neutropenia (three [9%]), and pancreatitis (two [6%]). Three (9%) patients discontinued due to adverse events and four (12%) patients experienced a total of six serious adverse events. There were no treatment-related deaths. 24 (80%; 90% CI 64·3-90·9) of 30 patients eligible for activity analysis had disease control at 12 weeks. INTERPRETATION Combination of olaparib and durvalumab showed promising antitumour activity and safety similar to that previously observed in olaparib and durvalumab monotherapy studies. Further research in a randomised setting is needed to determine predictors of therapeutic benefit and whether addition of durvalumab improves long-term clinical outcomes compared with olaparib monotherapy. FUNDING AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30324-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 484

Metadata

Authors
Domchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., Wang, D., Waqar, S. N., Lanasa, M., Rhee, J., Gao, H., Rocher-Ros, V., Jones, E. V., Gulati, S., Coenen-Stass, A., Kozarewa, I., Lai, Z., Angell, H. K., Opincar, L., Herbolsheimer, P., & Kaufman, B.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-09
Volume
21
Issue
9
Pages
1155-1164
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3047848114
Cited by
484
References
28
FWCI
22.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30324-7
The paper
Domchek, S. M., Postel-Vinay, S., Im, S.-A., Park, Y. H., Delord, J.-P., Italiano, A., Alexandre, J., You, B., Bastian, S., Krebs, M. G., Wang, D., Waqar, S. N., Lanasa, M., Rhee, J., Gao, H., Rocher-Ros, V., Jones, E. V., Gulati, S., Coenen-Stass, A., . . . Kaufman, B. (2020). Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30324-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.